Saturday 17 October 2026
Export ALPS’s income statement to Excel — free account
Alps Group Inc.
ALPS Healthcare Biotechnology
Alps Group Inc.’s revenue for fiscal 2026 (year ended March 2026) was $4.9 million, up 44.1% from fiscal 2025. In the quarter to September 2025, EPS fell 609.4% and free cash flow fell 26.5%, each against the same quarter a year earlier.
0.34
0.00
0.00%
Follow ALPS
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to March
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 9.77 | 9.79 | 10.19 | 10.81 | 0.56 | 0.23 |
Analyst estimates 2027–2029 Powerpack |
|||
| High | — | — | — | — | 9.86 | 10.21 | 11.67 | 12.40 | 15.00 | 1.39 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | — | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 2 | 3 | 5 | ||||
| Gross margin, % | — | — | — | — | — | — | — | 24.92 | 38.60 | 32.09 | |||||
| EBT | — | — | — | — | 0 | 1 | 2 | (1) | (3) | (2) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (75.03) | (42.86) | |||||
| Net income | 0 | — | — | — | 0 | 0 | 1 | (1) | (3) | (2) | |||||
| Depreciation | — | — | — | — | — | — | — | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 | ||||
| Earnings | — | — | — | — | (0.04) | 0.07 | 0.38 | (0.28) | (0.02) | (0.01) | |||||
| Cash flow | — | — | — | — | (0.11) | (0.21) | (0.41) | (0.59) | (0.01) | (0.02) | |||||
| Capex | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | — | (0.11) | (0.21) | (0.41) | (0.59) | (0.01) | (0.02) | |||||
| Book value | — | — | — | — | (1.08) | (1.18) | (2.11) | (3.10) | (0.01) | (0.02) | |||||
| Shares, m | — | — | — | — | 3 | 3 | 3 | 3 | 160 | 162 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 144.15 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| P/B | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| EV/FCF | — | — | — | — | — | — | — | (17.11) | (31.47) | (3.21) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (1) | (1) | (2) | (2) | (3) | ||||
| Capex | — | — | — | — | — | — | — | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | — | 0 | (1) | (1) | (2) | (2) | (3) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 1 | 0 | (4) | (7) | (6) | (4) | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | (1) | 0 | 0 | 0 | — | — | |||||
| Shareholders’ equity | — | — | — | — | (3) | (4) | (7) | (11) | (1) | (3) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | (0.10) | 0.19 | 1.79 | (6.01) | (46.40) | (28.48) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | (0.22) | (6.24) | (23.33) | 10.90 | 42.60 | 92.43 | |||||
Negative figures in brackets.
Fiscal years to Mar 2026
Charts ten years each
Alps Group Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| GANX Gain Therapeutics, Inc. | $58.1M | — (loss-making) | — (loss-making) | +27.78% (above 0%: growing) | n/m | +8.22% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR | $57.1M | — (loss-making) | — (loss-making) | +296.56% (above 0%: growing) | n/m | −23.48% (below 0%: shrinking) | 100.00% | (635.98%) | Compare |
| TENX Tenax Therapeutics, Inc. | $56.5M | — (loss-making) | — | −77.98% (below 0%: shrinking) | n/m | −125.93% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALPS Alps Group Inc. | $56.4M | — (loss-making) | — | — | n/m | −26.48% (below 0%: shrinking) | — | 0.00% | |
| ELOX Senesco Technologies Inc. | $55.3M | — (loss-making) | — | — | n/m | −144.34% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| GUTS Fractyl Health, Inc. | $55.2M | — (loss-making) | — (loss-making) | −57.14% (below 0%: shrinking) | n/m | +25.34% (above 0%: growing) | 100.00% | 0.00% | Compare |
| GOSS Gossamer Bio, Inc. | $54.3M | — (loss-making) | — (loss-making) | −19.59% (below 0%: shrinking) | n/m | +16.32% (above 0%: growing) | 100.00% | (282.25%) | Compare |
| RNTX Rein Therapeutics Inc. | $54.2M | — (loss-making) | — | — | n/m | −34.62% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| RNXT RenovoRx, Inc. | $53.7M | — (loss-making) | — (loss-making) | +115.40% (above 0%: growing) | n/m | −27.63% (below 0%: shrinking) | 84.27% | (368.43%) | Compare |
| Median of peers | $55.2M | — | — | +4.10% | — | −25.55% | 92.14% | 0.00% |
Alps Group Inc. (ALPS) key facts
- Strength: Alps Group Inc.’s revenue for fiscal 2026 (year ended March 2026) was $4.9 million, up 44.1% from fiscal 2025.
- Alps Group Inc. (ALPS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, ALPS traded at $0.34, a market capitalization of $56.4 million.
- Return on equity was 92.4% and debt-to-equity 0.00.